A Denali Therapeutics drug for the rare enzyme deficiency Hunter syndrome is still in pivotal testing, but the company has guidance from the FDA on a pathway to get this therapy to the market sooner.

Scientists have found a way to fine-tune a central fat-control pathway in the liver, reducing harmful blood triglycerides ...

A research team of the University Medical Center Mainz has succeeded in observing for the first time how G protein-coupled ...

For decades, scientists have investigated the neurokinin-1 receptor (NK1R) as a potential target for treating major ...

Chronic pain affects more than 50 million Americans, yet for decades, treatment options for pain that persists in the absence ...

AbbVie is joining the chase for new obesity drugs, but rather than getting a me-too GLP-1 drug, the pharmaceutical giant is landing rights to a clinical-stage molecule that goes after two novel ...

A team of researchers from the University of Utah and Sethera Therapeutics has uncovered a powerful new way to build more stable and drug-like peptides, opening the door to medicines that could target ...

A large team of researchers led by Wouter Karthaus, head of the Endocrine Therapy Resistance and Molecular Genetics Lab at ...

Researchers developed TLC-2716, a liver- and gut-targeted drug that selectively reduced LXR activity, lowering triglycerides, remnant cholesterol and fat in models and a Phase 1 trial without harming ...

"In this work we addressed one, and focused on a drug target in the gut, so we didn’t have to get the peptide drug lead across the gut-blood barrier, which also reduces the chance of any unwanted ...